391 related articles for article (PubMed ID: 29171189)
1. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
2. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
Reilly NM; Yard BD; Pittman DL
Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
[TBL] [Abstract][Full Text] [Related]
3. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
4. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
Wang C; Tang H; Geng A; Dai B; Zhang H; Sun X; Chen Y; Qiao Z; Zhu H; Yang J; Chen J; He Q; Qin N; Xie J; Tan R; Wan X; Gao S; Jiang Y; Sun FL; Mao Z
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26356-26365. PubMed ID: 33020270
[TBL] [Abstract][Full Text] [Related]
5. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
6. Characterization of DNA double-strand break repair pathways in diffuse large B cell lymphoma.
Gopalakrishnan V; Dahal S; Radha G; Sharma S; Raghavan SC; Choudhary B
Mol Carcinog; 2019 Feb; 58(2):219-233. PubMed ID: 30298948
[TBL] [Abstract][Full Text] [Related]
7. Sensitizing thermochemotherapy with a PARP1-inhibitor.
Oei AL; Vriend LE; van Leeuwen CM; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJ; Crezee J; Kanaar R; Kok HP; Krawczyk PM; Franken NA
Oncotarget; 2017 Mar; 8(10):16303-16312. PubMed ID: 27557507
[TBL] [Abstract][Full Text] [Related]
8. Understanding the DNA double-strand break repair and its therapeutic implications.
Ray U; Raghavan SC
DNA Repair (Amst); 2021 Oct; 106():103177. PubMed ID: 34325086
[TBL] [Abstract][Full Text] [Related]
9. Repair of G1 induced DNA double-strand breaks in S-G2/M by alternative NHEJ.
Yu W; Lescale C; Babin L; Bedora-Faure M; Lenden-Hasse H; Baron L; Demangel C; Yelamos J; Brunet E; Deriano L
Nat Commun; 2020 Oct; 11(1):5239. PubMed ID: 33067475
[TBL] [Abstract][Full Text] [Related]
10. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
Metzger MJ; Stoddard BL; Monnat RJ
DNA Repair (Amst); 2013 Jul; 12(7):529-34. PubMed ID: 23684799
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
12. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
Soni A; Siemann M; Pantelias GE; Iliakis G
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
[TBL] [Abstract][Full Text] [Related]
13. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
14. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
Shenoy TR; Boysen G; Wang MY; Xu QZ; Guo W; Koh FM; Wang C; Zhang LZ; Wang Y; Gil V; Aziz S; Christova R; Rodrigues DN; Crespo M; Rescigno P; Tunariu N; Riisnaes R; Zafeiriou Z; Flohr P; Yuan W; Knight E; Swain A; Ramalho-Santos M; Xu DY; de Bono J; Wu H
Ann Oncol; 2017 Jul; 28(7):1495-1507. PubMed ID: 28383660
[TBL] [Abstract][Full Text] [Related]
15. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
16. RB Regulates DNA Double Strand Break Repair Pathway Choice by Mediating CtIP Dependent End Resection.
Jiang Y; Yam JC; Tham CC; Pang CP; Chu WK
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271982
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining.
Bergs JW; Krawczyk PM; Borovski T; ten Cate R; Rodermond HM; Stap J; Medema JP; Haveman J; Essers J; van Bree C; Stalpers LJ; Kanaar R; Aten JA; Franken NA
DNA Repair (Amst); 2013 Jan; 12(1):38-45. PubMed ID: 23237939
[TBL] [Abstract][Full Text] [Related]
18. The dystonia gene THAP1 controls DNA double-strand break repair choice.
Shinoda K; Zong D; Callen E; Wu W; Dumitrache LC; Belinky F; Chari R; Wong N; Ishikawa M; Stanlie A; Multhaupt-Buell T; Sharma N; Ozelius L; Ehrlich M; McKinnon PJ; Nussenzweig A
Mol Cell; 2021 Jun; 81(12):2611-2624.e10. PubMed ID: 33857404
[TBL] [Abstract][Full Text] [Related]
19. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
20. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.
Hilmi K; Jangal M; Marques M; Zhao T; Saad A; Zhang C; Luo VM; Syme A; Rejon C; Yu Z; Krum A; Fabian MR; Richard S; Alaoui-Jamali M; Orthwein A; McCaffrey L; Witcher M
Sci Adv; 2017 May; 3(5):e1601898. PubMed ID: 28560323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
